# Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma

> **NCT05448677** · PHASE2 · TERMINATED · sponsor: **University Hospital, Grenoble** · enrollment: 3 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Ezurpimtrostat
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05448677
- **Lead sponsor:** University Hospital, Grenoble
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-15
- **Primary completion:** 2024-03-08
- **Final completion:** 2024-03-08
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study terminated due to recruitement issues
- **Last updated:** 2025-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05448677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05448677, "Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05448677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*